Lista de obras -

A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD.

artículo científico publicado en 2017

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

artículo científico publicado en 2020

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

artículo científico publicado en 2011

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

artículo científico publicado en 2014

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

artículo científico publicado en 2017

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

artículo científico publicado en 2014

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

artículo científico publicado en 2011

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia

artículo científico publicado en 2014

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

artículo científico publicado en 2014

Immune cell phenotype and functional defects in Netherton syndrome

scientific article published on 26 November 2018

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

artículo científico publicado en 2019

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

artículo científico publicado en 2012

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

artículo científico publicado en 2010

Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

artículo científico publicado en 2017

Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.

artículo científico publicado en 2010

Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia

artículo científico publicado en 2015

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

artículo científico publicado en 2012

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma

artículo científico publicado en 2022

T cells and cancer - why do the killers become exhausted?

artículo científico publicado en 2016

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

artículo científico publicado en 2017

Lista de obras de

A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD.

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Immune cell phenotype and functional defects in Netherton syndrome

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.

Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma

T cells and cancer - why do the killers become exhausted?

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.